BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...diabetes portfolio and guided its expansion to novel technologies including gene therapy.Retinal degenerative diseases play jCyte Inc. hired...
...the Friedreich’s Ataxia Research Alliance. BC Staff Day One Biopharmaceuticals LLC Coherus BioSciences Inc. Antios Therapeutics Inc. ArsenalBio Affinia Therapeutics Artelo Biosciences Inc. jCyte Inc. Cue...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...has a candidate in Phase II testing for inflammatory bowel disease (IBD).Regenerative cell therapy play jCyte Inc....
BioCentury | Jul 29, 2020
Product Development

July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

...treat macular edema in patients with retinal vein occlusion. jCyte planning pivotal stem cell trial jCyte Inc....
...BVCA results were still quite strong, and the secondary endpoints were quite aligned” (see “ jCyte-Santen...
...Farxiga (Brand), BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Furoscix Infusor (Furosemide, ScFurosemide) BeiGene Ltd. Aerie Pharmaceuticals Inc. jCyte Inc. Nabriva...
BioCentury | May 9, 2020
Deals

jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access

...Cash from an ex-U.S. licensing deal with Santen, plus years of grants from CIRM, position jCyte...
...therapy is in the crossover portion of a Phase IIb study to treat retinitis pigmentosa. jCyte Inc....
...to continue development of jCell in retinitis pigmentosa and begin a global Phase III trial, jCyte...
BioCentury | Jul 18, 2019
Finance

As funding dwindles, CIRM believes goals within reach

...the University of California Irvine that has reached Phase IIb testing in the hands of jCyte Inc....
...California Institute for Regenerative Medicine (CIRM), Oakland, Calif. Forty Seven Inc. (NASDAQ:FTSV), Menlo Park, Calif. jCyte Inc....
BioCentury | Jul 27, 2017
Strategy

FDA’s regeneration

...Repair Cell technology Advanced heart failure due to ischemic dilated cardiomyopathy Phase II May 2 jCyte Inc....
BioCentury | Dec 6, 2016
Clinical News

jCell: Completed Ph I/IIa enrollment

...in an open-label, U.S. Phase I/IIa trial evaluating single intravitreal injections of 0.5-3 million hRPCs. jCyte Inc....
...field testing and fluorescein angiography Status: Completed Phase I/IIa enrollment Milestone: Start Phase IIb (2017) Alicia Parker jCell jCyte...
Items per page:
1 - 7 of 7
BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...diabetes portfolio and guided its expansion to novel technologies including gene therapy.Retinal degenerative diseases play jCyte Inc. hired...
...the Friedreich’s Ataxia Research Alliance. BC Staff Day One Biopharmaceuticals LLC Coherus BioSciences Inc. Antios Therapeutics Inc. ArsenalBio Affinia Therapeutics Artelo Biosciences Inc. jCyte Inc. Cue...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...has a candidate in Phase II testing for inflammatory bowel disease (IBD).Regenerative cell therapy play jCyte Inc....
BioCentury | Jul 29, 2020
Product Development

July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

...treat macular edema in patients with retinal vein occlusion. jCyte planning pivotal stem cell trial jCyte Inc....
...BVCA results were still quite strong, and the secondary endpoints were quite aligned” (see “ jCyte-Santen...
...Farxiga (Brand), BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Furoscix Infusor (Furosemide, ScFurosemide) BeiGene Ltd. Aerie Pharmaceuticals Inc. jCyte Inc. Nabriva...
BioCentury | May 9, 2020
Deals

jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access

...Cash from an ex-U.S. licensing deal with Santen, plus years of grants from CIRM, position jCyte...
...therapy is in the crossover portion of a Phase IIb study to treat retinitis pigmentosa. jCyte Inc....
...to continue development of jCell in retinitis pigmentosa and begin a global Phase III trial, jCyte...
BioCentury | Jul 18, 2019
Finance

As funding dwindles, CIRM believes goals within reach

...the University of California Irvine that has reached Phase IIb testing in the hands of jCyte Inc....
...California Institute for Regenerative Medicine (CIRM), Oakland, Calif. Forty Seven Inc. (NASDAQ:FTSV), Menlo Park, Calif. jCyte Inc....
BioCentury | Jul 27, 2017
Strategy

FDA’s regeneration

...Repair Cell technology Advanced heart failure due to ischemic dilated cardiomyopathy Phase II May 2 jCyte Inc....
BioCentury | Dec 6, 2016
Clinical News

jCell: Completed Ph I/IIa enrollment

...in an open-label, U.S. Phase I/IIa trial evaluating single intravitreal injections of 0.5-3 million hRPCs. jCyte Inc....
...field testing and fluorescein angiography Status: Completed Phase I/IIa enrollment Milestone: Start Phase IIb (2017) Alicia Parker jCell jCyte...
Items per page:
1 - 7 of 7